HLN Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
NYSE · Pharmaceuticals · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Mar 13, 2026HLN Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
HLN Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Tentang Haleon plc American Depositary Shares (Each representing two Ordinary Shares) Tinjauan perusahaan dari Wikipedia
Haleon plc adalah perusahaan kesehatan konsumen multinasional Inggris dengan kantor pusat di Weybridge, Inggris. Perusahaan ini adalah salah satu bisnis perawatan kesehatan konsumen terbesar di dunia, dengan merek termasuk pasta gigi Sensodyne, obat penghilang rasa sakit Panadol dan Advil serta vitamin Centrum. Perusahaan ini adalah pemimpin global dalam obat bebas dengan pangsa pasar 7,3 persen.
Haleon didirikan pada 18 Juli 2022 sebagai pemisahan perusahaan dari GSK.
Sir David Lewis adalah ketua, dengan Brian McNamara sebagai CEO. Haleon terdaftar di London Stock Exchange dan merupakan komponen dari FTSE 100, dengan listing sekunder di New York Stock Exchange. Penjualan tahunan berjumlah sekitar £10 miliar di 120 pasar pada tahun 2020.
Di Indonesia, Haleon beroperasi di bawah dua perusahaan yaitu PT Sterling Products Indonesia yang mengemas dan merilis Panadol serta Scott's Emulsion, dan PT Haleon Indonesia Trading (sebelumnya bernama PT GSK Consumer Healthcare Indonesia) yang mendistribusikan Sensodyne serta Polident.
Sejarah
GSK dan Pfizer menggabungkan bisnis layanan kesehatan konsumen mereka pada tahun 2019. GSK memiliki lebih dari dua pertiga dari usaha patungan tersebut, dan Pfizer memegang sisanya.
GSK mengumumkan rencana untuk memisahkan Haleon pada tahun 2018, untuk memberikan "fokus ekstra dan daya tembak ekstra kepada pembuat obat yang lelah dengan mempersiapkan dan menghentikan divisi konsumen".
Unilever menawarkan £50 miliar untuk bisnis tersebut pada tahun 2022, dalam tawaran yang ditolak GSK. Nestlé mengkaji kemungkinan penawaran bersama dengan Reckitt.
Usulan spin-off merek perawatan bibir ChapStick senilai $600 juta diperdebatkan pada tahun 2023.
Operasi
Kesehatan mulut menyumbang 28,5 persen dari pendapatan pada tahun 2021.
Aset kotor berjumlah lebih dari £45 miliar pada 31 Maret 2022.
Merek
Merek meliputi:
Abreva (Dokosanol)
Advil (Ibuprofen)
alli (Orlistat)
Aquafresh (kesehatan mulut)
Astring-o-Sol (kesehatan mulut)
Be-Total (pemimpin pasar vitamin di Italia)
Beechams Cold & Flu dan Perawat Malam/Siang (perawatan pilek dan flu)
Biotene (kesehatan mulut)
Meningkatkan (nutrisi)
Bernapas dengan benar (pernapasan)
Centrum (vitamin dan alami)
Cetebe (vitamin dan alami)
Chlorhexamed (kesehatan mulut)
Cholinex (analgesik dan saluran pernapasan)
Citrucel (pencernaan)
Coldrex (pengobatan pilek dan flu)
Commit Lozenge (berhenti merokok)
Berhenti Berkomitmen (pengganti nikotin)
Corega (kesehatan mulut)
Corsodyl (kesehatan mulut)
Crocin (analgesik dan saluran pernapasan)
Dr Best (kesehatan mulut)
ENO (saluran pencernaan)
Eumovate (dermatologis)
Fenbid (analgesik dan saluran pernapasan)
Flonase (flutikason propionat)
Formigran (analgesik/triptan)
Grand-PA (sakit kepala/sakit gigi/nyeri dan demam)
Hinds (dermatologis)
Junior Horlicks (nutrisi)
Iodex (pereda nyeri)
Iodosan (pengobatan pilek dan flu)
Macleans (kesehatan mulut)
Maltova (nutrisi)
Maxinutrition (nutrisi)
Med-Lemon (obat panas, dingin dan flu)
Medacalm (vitamin dan alami)
Nicorette (pengganti nikotin)
Perawat Malam (obat pilek dan flu)
NiQuitin CQ/ Nicoderm CQ/ Nicabate (pengganti nikotin)
Odol (kesehatan mulut)
Odol-med3 (kesehatan mulut)
Os-kal (kesehatan mulut)
Otrivin
Panadeine (analgesik dan saluran pernapasan)
Panadol (analgesik dan saluran pernapasan)
parodontax (kesehatan mulut)
Piriton/Piriteze (anti alergi)
Polident (kesehatan mulut)
Poligrip Ultra (kesehatan mulut)
Robitussin (pernapasan)
Rutinoscorbin (vitamin dan alami)
Scott's Emulsion (vitamin dan bahan alami)
Sensodyne (kesehatan mulut)
Shumitect (kesehatan mulut)
Solpadeine (analgesik dan saluran pernapasan)
Super Poligrip (kesehatan mulut)
Super Wernet's (kesehatan mulut)
Synthol (kesehatan mulut)
Theraflu (Pernafasan)
Triaminic
Tum (pencernaan)
Viva (vitamin dan natural), asal: Nepal
Voltaren (anti inflamasi)
Zovirax (dermatologis)
Kepemilikan
Pada 2022, Pfizer memiliki 32 persen saham Haleon, sedangkan GSK mempertahankan 13 persen saham.
Referensi
Pranala luar
Situs web resmi
Data bisnis Haleon:
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | HLN | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E | 54.6rata-rata 5T ≈64.5 | ≈64.5 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | HLN | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Gross Margin (Margin Kotor) | 64.2%rata-rata 5T ≈61.3% | ≈61.3% | · | · | |
| Operating Margin (Margin Operasi) | 21.9%rata-rata 5T ≈19.0% | ≈19.0% | · | · | |
| EBITDA Margin (Margin EBITDA) | 25.1%rata-rata 5T ≈19.8% | ≈19.8% | · | · | |
| Pretax Margin (Margin Sebelum Pajak) | 19.5%rata-rata 5T ≈16.5% | ≈16.5% | · | · | |
| Net Profit Margin (Margin Laba Bersih) | 15.1%rata-rata 5T ≈11.7% | ≈11.7% | · | · | |
| ROA | 5.0%rata-rata 5T ≈3.8% | ≈3.8% | · | · | |
| ROE | 10.2%rata-rata 5T ≈7.6% | ≈7.6% | · | · | |
| ROIC | 11.5%rata-rata 5T ≈9.5% | ≈9.5% | · | · |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | HLN | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Current Ratio (Rasio Lancar) | 0.9rata-rata 5T ≈1.0 | ≈1.0 | · | · | |
| Quick Ratio (Rasio Cepat) | 0.7rata-rata 5T ≈0.7 | ≈0.7 | · | · | |
| Interest Coverage (Cakupan Bunga) | 7.1rata-rata 5T ≈6.2 | ≈6.2 | · | · |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Data fundamental belum cukup untuk menghitung grup rasio ini.
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | HLN | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.3rata-rata 5T ≈0.3 | ≈0.3 | · | · | |
| Inventory Turnover (Perputaran Persediaan) | 3.6rata-rata 5T ≈3.5 | ≈3.5 | · | · | |
| Receivables Turnover (Perputaran Piutang) | 5.4rata-rata 5T ≈5.6 | ≈5.6 | · | · | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$449.6K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
| Tanggal ex-dividen | Jumlah | Mata Uang | Imbal Hasil |
|---|---|---|---|
| Agu 14, 2026 | $0,06 | USD | ≈2.0% |
| Apr 10, 2026 | $0,13 | USD | ≈1.9% |
| Agu 15, 2025 | $0,06 | USD | ≈1.8% |
| Apr 25, 2025 | $0,12 | USD | ≈1.7% |
| Agu 16, 2024 | $0,05 | USD | ≈1.6% |
| Mar 14, 2024 | $0,11 | USD | ≈1.8% |
| Agu 24, 2023 | $0,05 | USD | ≈1.3% |
| Mar 16, 2023 | $0,06 | USD | ≈0.73% |
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 31 Des. 2024 | $0.04 | $0.04 | 7.2% | |
| 30 Sep. 2024 | $0.05 | $0.05 | -1.9% | |
| 30 Juni 2024 | $0.04 | $0.04 | 2.3% | |
| 31 Maret 2024 | $0.05 | $0.05 | 7.6% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $11.03B | $11.23B | $11.30B | $10.86B | $9.54B | |
| Cost of Revenue | $3.95B | $4.41B | $4.55B | $4.28B | $3.60B | |
| Gross Profit | $7.08B | $6.82B | $6.75B | $6.58B | $5.95B | |
| R&D Expense | $316M | $298M | $311M | $300M | $257M | |
| SG&A Expense | $4.36B | $4.45B | $4.41B | $4.48B | $4.09B | |
| Operating Income | $2.41B | $2.21B | $2.00B | $1.82B | $1.64B | |
| Interest Expense | $340M | $384M | $402M | $258M | $19M | |
| Interest Income | $78M | $82M | $34M | $51M | $17M | |
| Pretax Income | $2.15B | $1.91B | $1.63B | $1.62B | $1.64B | |
| Income Tax | $472M | $435M | $517M | $499M | $197M | |
| Net Income | $1.67B | $1.44B | $1.05B | $1.06B | $1.39B | |
| EPS (Basic) | $0.19 | $0.16 | $0.11 | $0.12 | $0.15 | |
| EPS (Diluted) | $0.18 | $0.16 | $0.11 | $0.12 | $0.15 | |
| Shares (Basic) | 8,982,000,000 | 9,132,000,000 | 9,233,000,000 | 9,235,000,000 | 9,234,573,831 | |
| Shares (Diluted) | 9,026,000,000 | 9,175,000,000 | 9,263,000,000 | 9,239,000,000 | 9,235,000,000 | |
| EBITDA | $2.77B | $2.21B | $2.00B | $1.82B | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.32B | $2.25B | $1.04B | $684M | $414M | |
| Receivables | $2.06B | $2.06B | $1.86B | $1.88B | $2.21B | |
| Inventory | $1.02B | $1.19B | $1.41B | $1.35B | $951M | |
| Current Assets | $4.55B | $5.72B | $4.82B | $4.06B | $5.25B | |
| PP&E (Net) | $1.87B | $1.81B | $1.78B | $1.76B | $1.56B | |
| Goodwill | $8.13B | $8.20B | $8.32B | $8.40B | $8.25B | |
| Total Assets | $32.63B | $34.31B | $34.05B | $34.81B | $34.45B | |
| Accounts Payable | $3.73B | $3.71B | $3.53B | $3.62B | $3.00B | |
| Current Liabilities | $4.93B | $5.81B | $4.64B | $4.37B | $4.24B | |
| Total Liabilities | $16.15B | $18.09B | $17.33B | $18.36B | $7.97B | |
| Retained Earnings | $27.85B | $27.27B | $27.47B | $26.73B | $37.54B | |
| Stockholders' Equity | $16.43B | $16.17B | $16.61B | $16.33B | $26.36B |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| D&A | $360M | $324M | $309M | · | · | |
| Other Non-cash | $607M | · | · | · | · | |
| Operating Cash Flow | $2.63B | $2.30B | $2.10B | $2.06B | $1.36B | |
| CapEx | $322M | $250M | $234M | $304M | $228M | |
| Investing Cash Flow | $-346M | $528M | $-134M | $-8.78B | $-33M | |
| Financing Cash Flow | $-3.14B | $-1.54B | $-1.57B | $6.91B | $-1.24B | |
| Free Cash Flow | $2.31B | $2.05B | $1.87B | $1.76B | · | |
| Levered FCF | $2.05B | $1.75B | $1.59B | $1.58B | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 64.2% | 60.8% | 59.7% | 60.6% | · | |
| Operating Margin | 21.9% | 19.6% | 17.7% | 16.8% | · | |
| Net Margin | 15.1% | 12.8% | 9.3% | 9.8% | · | |
| Pretax Margin | 19.5% | 17.0% | 14.4% | 14.9% | · | |
| EBITDA Margin | 25.1% | 19.6% | 17.7% | 16.8% | · | |
| ROA | 5.0% | 4.2% | 3.0% | 3.1% | · | |
| ROE | 10.2% | 8.8% | 6.4% | 5.0% | · | |
| ROIC | 11.5% | 10.5% | 8.2% | 7.7% | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 1.0 | 1.0 | 0.9 | · | |
| Quick Ratio | 0.7 | 0.7 | 0.6 | 0.6 | · | |
| Interest Coverage | 7.1 | 5.7 | 5.0 | 7.1 | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.3 | 0.3 | · | |
| Inventory Turnover | 3.6 | 3.4 | 3.3 | 3.7 | · | |
| Receivables Turnover | 5.4 | 5.7 | 6.0 | 5.3 | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue / Share | $1.22 | $1.22 | $1.22 | $1.18 | · | |
| Cash Flow / Share | $0.29 | $0.25 | $0.23 | $0.22 | · | |
| EPS (TTM) | $0.18 | $0.16 | $0.11 | $0.12 | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue TTM | $11.03B | $11.23B | $11.30B | $10.86B | · | |
| Net Income TTM | $1.67B | $1.44B | $1.05B | $1.06B | · | |
| P/E | 54.6 | 60.8 | 72.8 | 69.6 | · | |
| Earnings Yield | 1.8% | 1.7% | 1.4% | 1.4% | · |
Per Saham
| Metrik | Tren | Q4 2023 |
|---|---|---|
| EPS (TTM) | $0.11 |
Valuasi (TTM)
| Metrik | Tren | Q4 2023 |
|---|---|---|
| Revenue TTM | $11.30B | |
| Net Income TTM | $1.05B | |
| P/E | 72.8 | |
| Earnings Yield | 1.4% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $11.03B | $11.23B | $11.30B | $10.86B | $9.54B |
| Margin Kotor % | 64.2% | 60.8% | 59.7% | 60.6% | · |
| Margin Operasi % | 21.9% | 19.6% | 17.7% | 16.8% | · |
| Laba Bersih | $1.67B | $1.44B | $1.05B | $1.06B | $1.39B |
| EPS Dilusian | $0.18 | $0.16 | $0.11 | $0.12 | $0.15 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rasio Lancar | 0.9 | 1.0 | 1.0 | 0.9 | · |
| Rasio Cepat | 0.7 | 0.7 | 0.6 | 0.6 | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $2.31B | $2.05B | $1.87B | $1.76B | · |
Pemilik institusional (13F) 681 pengaju · $5.5B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 82 (-17 vs Kuartal sebelumnya) | 56 (-3 vs Kuartal sebelumnya) | 215 (+5 vs Kuartal sebelumnya) | 214 (+41 vs Kuartal sebelumnya) | +23.5M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| Dodge & Cox | $1.398.888.950 | 149.934.507 | 25,61% | Saham |
| FMR LLC | $1.128.848.360 | 120.991.250 | 20,67% | Saham |
| Clearbridge Investments, LLC | $301.752.032 | 32.342.126 | 5,52% | Saham |
| MORGAN STANLEY | $181.578.262 | 19.461.762 | 3,32% | Saham |
| HARRIS ASSOCIATES L P | $157.054.241 | 16.833.252 | 2,88% | Saham |
| Harding Loevner LP | $147.817.757 | 15.414.796 | 2,71% | Saham |
| Nuveen, LLC | $143.055.570 | 15.332.859 | 2,62% | Saham |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $132.316.353 | 14.181.817 | 2,42% | Saham |
| BANK OF AMERICA CORP /DE/ | $101.231.407 | 10.850.097 | 1,85% | Saham |
| JPMORGAN CHASE & CO | $100.991.616 | 10.824.395 | 1,85% | Saham |
| Point72 Asset Management, L.P. | $86.435.499 | 9.264.255 | 1,58% | Saham |
| RAYMOND JAMES FINANCIAL INC | $67.911.909 | 7.278.875 | 1,24% | Saham |
| NORGES BANK | $66.942.750 | 7.175.000 | 1,23% | Saham |
| Aristotle Capital Management, LLC | $66.153.974 | 7.090.436 | 1,21% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $65.752.882 | 7.116.095 | 1,20% | Saham |
| Douglas Lane & Associates, LLC | $62.439.995 | 6.692.390 | 1,14% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $58.555.920 | 6.276.154 | 1,07% | Saham |
| GOLDMAN SACHS GROUP INC | $50.330.141 | 5.394.442 | 0,92% | Saham |
| WELLS FARGO & COMPANY/MN | $45.944.004 | 4.924.330 | 0,84% | Saham |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $44.634.617 | 4.783.989 | 0,82% | Saham |
| Bank Julius Baer & Co. Ltd, Zurich | $41.842.598 | 4.481.615 | 0,77% | Saham |
| First Eagle Investment Management, LLC | $39.417.910 | 4.224.856 | 0,72% | Saham |
| BlackRock, Inc. | $37.110.438 | 3.977.539 | 0,68% | Saham |
| NORTHERN TRUST CORP | $36.993.552 | 3.965.011 | 0,68% | Saham |
| CIBC Bancorp USA Inc. | $35.986.757 | 3.856.063 | 0,66% | Saham |
| JANE STREET GROUP, LLC | $34.232.852 | 3.669.116 | 0,63% | Saham |
| ROYAL BANK OF CANADA | $31.587.000 | 3.385.489 | 0,58% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $30.542.528 | 3.273.583 | 0,56% | Saham |
| Bank of New York Mellon Corp | $30.532.830 | 3.272.543 | 0,56% | Saham |
| VAN ECK ASSOCIATES CORP | $28.880.558 | 3.095.451 | 0,53% | Saham |
| WCM INVESTMENT MANAGEMENT, LLC | $24.474.885 | 2.623.246 | 0,45% | Saham |
| STIFEL FINANCIAL CORP | $24.300.563 | 2.604.559 | 0,44% | Saham |
| D. E. Shaw & Co., Inc. | $23.560.984 | 2.525.293 | 0,43% | Saham |
| PRINCIPAL FINANCIAL GROUP INC | $19.823.143 | 2.124.667 | 0,36% | Saham |
| LPL Financial LLC | $18.997.330 | 2.036.156 | 0,35% | Saham |
| Goodman Financial Corp | $16.823.173 | 1.803.127 | 0,31% | Saham |
| Night Squared LP | $16.108.758 | 1.726.555 | 0,29% | Saham |
| CLARK ESTATES INC/NY | $15.861.000 | 1.700.000 | 0,29% | Saham |
| CITADEL ADVISORS LLC | $15.517.022 | 1.663.132 | 0,28% | Saham |
| KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | $14.574.715 | 1.562.134 | 0,27% | Saham |
| Toroso Investments, LLC | $14.498.832 | 1.434.108 | 0,27% | Saham |
| CITIGROUP INC | $14.065.333 | 1.507.538 | 0,26% | Saham |
| Grantham, Mayo, Van Otterloo & Co. LLC | $13.864.588 | 1.486.022 | 0,25% | Saham |
| FRANKLIN RESOURCES INC | $12.087.393 | 1.295.541 | 0,22% | Saham |
| Cubist Systematic Strategies, LLC | $11.034.974 | 1.230.209 | 0,20% | Saham |
| Quantinno Capital Management LP | $10.740.595 | 1.151.189 | 0,20% | Saham |
| UBS Group AG | $10.487.611 | 1.124.074 | 0,19% | Saham |
| ABC ARBITRAGE SA | $10.349.722 | 1.109.295 | 0,19% | Saham |
| Russell Investments Group, Ltd. | $10.337.943 | 1.108.033 | 0,19% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $10.280.447 | 1.101.870 | 0,19% | Saham |
Aktivis & pemilik 5%+ 2 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Pfizer Inc. ×5 pengajuan | 24 Maret 2025 | 0,00% | Amandemen | · | SEC |
| Pfizer Inc. (“ Pfizer ” or the “ Reporting Person ”) ×11 pengajuan | 3 Okt. 2024 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 30 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| EWU · iShares Trust | 1,26% | 10.265.689 SH | 11 Sep. 2026 | Harian |
| EFAV · iShares Trust | 0,63% | 7.499.966 SH | 11 Sep. 2026 | Harian |
| IXJ · iShares Trust | 0,51% | 4.673.180 SH | 11 Sep. 2026 | Harian |
| IDLV · Invesco Exchange-Traded Fund Trust … | 0,45% | 319.679 SH | 1 Okt. 2026 | Harian |
| DMXF · iShares Trust | 0,36% | 751.360 SH | 11 Sep. 2026 | Harian |
| EFV · iShares Trust | 0,36% | 24.941.478 SH | 11 Sep. 2026 | Harian |
| IEV · iShares Trust | 0,28% | 1.028.600 SH | 11 Sep. 2026 | Harian |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,26% | 21.371.662 SH | 19 Agu 2026 | Harian |
| IEUR · iShares Trust | 0,25% | 5.082.548 SH | 11 Sep. 2026 | Harian |
| PABD · iShares Trust | 0,24% | 176.612 SH | 11 Sep. 2026 | Harian |
| IVLU · iShares Trust | 0,24% | 2.488.919 SH | 11 Sep. 2026 | Harian |
| SPWO · SP Funds Trust | 0,22% | 44.837 NS | 31 Juli 2026 | N-PORT |
| EFA · iShares Trust | 0,18% | 31.397.031 SH | 11 Sep. 2026 | Harian |
| PXF · Invesco Exchange-Traded Fund Trust … | 0,16% | 1.032.563 SH | 1 Okt. 2026 | Harian |
| IEFA · iShares Trust | 0,16% | 66.967.942 SH | 11 Sep. 2026 | Harian |
| IMFL · Invesco Exchange-Traded Self-Indexe… | 0,15% | 342.307 SH | 1 Okt. 2026 | Harian |
| IDEV · iShares Trust | 0,13% | 9.519.085 SH | 11 Sep. 2026 | Harian |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,12% | 86.891.139 SH | 19 Agu 2026 | Harian |
| VSGX · VANGUARD WORLD FUND | 0,12% | 1.791.289 SH | 19 Agu 2026 | Harian |
| ESGD · iShares Trust | 0,11% | 2.830.261 SH | 11 Sep. 2026 | Harian |
| ACWX · iShares Trust | 0,10% | 2.872.444 SH | 11 Sep. 2026 | Harian |
| VEU · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,10% | 20.804.577 SH | 19 Agu 2026 | Harian |
| IXUS · iShares Trust | 0,09% | 12.141.022 SH | 11 Sep. 2026 | Harian |
| VXUS · VANGUARD STAR FUNDS | 0,09% | 130.756.991 SH | 19 Agu 2026 | Harian |
| TOK · iShares Trust | 0,05% | 24.876 SH | 11 Sep. 2026 | Harian |
| URTH · iShares, Inc. | 0,04% | 785.701 SH | 11 Sep. 2026 | Harian |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 7.551.644 SH | 19 Agu 2026 | Harian |
| ACWI · iShares Trust | 0,04% | 2.652.598 SH | 11 Sep. 2026 | Harian |
| CRBN · iShares Trust | 0,03% | 89.587 SH | 11 Sep. 2026 | Harian |
| DFAX · Dimensional ETF Trust | 0,00% | 13.593 NS | 31 Juli 2026 | N-PORT |
HLN Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
Target Harga 12 Bulan
5 analis · 2026-09-29Target rata-rata $11.93 +35,6%
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.